"Pfizer's Bold Move: Revitalizing Investor Interest with New Cancer Drugs"
Pfizer is facing a significant challenge as its shares have plummeted, and it aims to address this by focusing on new cancer drugs, including the recent acquisition of Seagen for $43 billion. The company's executives are holding an investor briefing to persuade shareholders of the potential payoff. CEO Albert Bourla is adamant about the deal's potential, despite the market's skepticism.